leukemia
Kura Oncology Advances Phase I/II Trial for Menin Inhibitor in Advanced AML
The company is currently enrolling around a dozen AML patients with NPM1 mutations or KMT2A rearrangements into two Phase Ib cohorts.
Aleta Biotherapeutics, Cancer Research UK Partner on CAR T-Cell Engager Trial
Cancer Research UK will conduct a Phase I/II trial of ALETA-001 for lymphoma and leukemia patients who have stopped responding to anti-CD19 CAR T-cell therapy.
EHA Virtual Congress 2021 Roundup: Roche, Mustang Bio, Gilead, Innovent, Autolus, Curis
Companies presented the latest data on precision oncology therapeutics for blood cancers at the meeting held from June 9-17.
FDA Approves Blueprint Medicines' Ayvakit for Advanced Systemic Mastocytosis
The approval was based on pooled data from Phase I and Phase II trials in advanced SM patients that showed an overall response rate of 57 percent.
Kurome Therapeutics Raises $15 Million in Series A Financing
The preclinical company is developing dual IRAK1/4 and panFLT3 inhibitors for the treatment of acute myeloid leukemia.